{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:47:57Z","timestamp":1792108077034,"version":"4.4.0"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101125","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:15:18Z","timestamp":1769793318000},"page":"101125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["CAR T- cell therapy: A promising novel approach for treatment of cancer"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1583-6022","authenticated-orcid":false,"given":"Mahesh Kumar","family":"Posa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Parveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhranshu","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ctarc.2026.101125_bib0001","first-page":"86","article-title":"Car-T cell therapy: current advances and future research possibilities","volume":"2","author":"Ahmed","year":"2021","journal-title":"J. Sci. Res. Med. Biol. Sci."},{"key":"10.1016\/j.ctarc.2026.101125_bib0002","doi-asserted-by":"crossref","unstructured":"P. Bories and L. Ysebaert, Chimeric antigen receptor T cells, vol. 108, no. 10. 2021. doi: 10.1016\/j.bulcan.2021.08.003.","DOI":"10.1016\/j.bulcan.2021.08.003"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101125_bib0003","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/pharmaceutics16091228","article-title":"Nanotechnology in advancing chimeric antigen receptor T cell therapy for cancer treatment","volume":"16","author":"Kang","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ctarc.2026.101125_bib0004","first-page":"475","article-title":"Chimeric antigen receptor T cell therapy: a cutting-edge therapy for multiple myeloma","volume":"6","author":"Sinha","year":"2022","journal-title":"Biomed. Transl. Res. Drug Des. Discov."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101125_bib0005","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178558","article-title":"IL-2-inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells","volume":"135","author":"Fu","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0006","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ctarc.2026.101125_bib0007","article-title":"Combining chemotherapy with CAR-T cell therapy in treating solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2026.101125_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1389227","article-title":"Case report: donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed\/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission","volume":"15","author":"Miao","year":"2024","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101125_bib0009","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1158\/2326-6066.CIR-21-0269","article-title":"Engineered T-cell receptor T cells for cancer immunotherapy","volume":"9","author":"Greenbaum","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101125_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70067","article-title":"The design of retroviral vectors used in the CAR-T products, risk management, and future perspective","volume":"6","author":"Yin","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.ctarc.2026.101125_bib0011","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-1-0716-2441-8_4","article-title":"Generation of redirected engineered Human chimeric antigen receptor (CAR) T cells","volume":"2521","author":"Bunse","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ctarc.2026.101125_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.803947","article-title":"Deciphering innate immune cell-tumor microenvironment crosstalk at a single-cell level","volume":"10","author":"Sugimura","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101125_bib0013","first-page":"967","article-title":"Advances in allogeneic chimeric antigen receptor T cells","volume":"45","author":"Zhao","year":"2023","journal-title":"Acta Acad. Med. Sin."},{"key":"10.1016\/j.ctarc.2026.101125_bib0014","doi-asserted-by":"crossref","unstructured":"Springuel, L., Lonez, C., Alexandre, B., Van Cutsem, E., Machiels, J.-P.H., Van Den Eynde, M., Prenen, H., Hendlisz, A., Shaza, L., Carrasco, J., Canon, J.-L., Opyrchal, M., Odunsi, K., Rottey, S., Gilham, D.E., Flament, A., & Lehmann, F.F. (2019). Chimeric antigen receptor-T cells for targeting solid tumors: current challenges and existing strategies. BioDrugs, 33(5), 515\u2013537. https:\/\/doi.org\/10.1007\/s40259-019-00368-z.","DOI":"10.1007\/s40259-019-00368-z"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101125_bib0015","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101125_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011238","article-title":"Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach","volume":"13","author":"Cao","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ctarc.2026.101125_bib0017","doi-asserted-by":"crossref","DOI":"10.7748\/ns.2024.e12349","article-title":"Chimeric antigen receptor (CAR) T-cell therapy: an overview for nurses","author":"Thoms","year":"2024","journal-title":"Nurs. Stand."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/ph17010139","article-title":"Harnessing biomaterials for safeguarding chimeric antigen receptor T cell therapy: an artful expedition in mitigating adverse effects","volume":"17","author":"Chen","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ctarc.2026.101125_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.738456","article-title":"Genetic modification of cytokine signaling to enhance efficacy of CAR T cell therapy in solid tumors","volume":"12","author":"Ghahri-Saremi","year":"2021","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.ctarc.2026.101125_bib0020","doi-asserted-by":"crossref","first-page":"8242","DOI":"10.3390\/ijms23158242","article-title":"Cardiotoxicity of chimeric antigen receptor T-cell (CAR-T) therapy: pathophysiology, clinical implications, and echocardiographic assessment","volume":"23","author":"Nenna","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"39","key":"10.1016\/j.ctarc.2026.101125_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202506429","article-title":"Synthetic biology and biomaterials strategies to deceive the tumor microenvironment in CAR-T immunotherapy","volume":"21","author":"Marsico","year":"2025","journal-title":"Small"},{"issue":"26","key":"10.1016\/j.ctarc.2026.101125_bib0022","article-title":"Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies","volume":"13","author":"Xiao","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0023","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nyas.14724","article-title":"Strategies to overcome the side effects of chimeric antigen receptor T cell therapy","volume":"1510","author":"Mirzaee Godarzee","year":"2022","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101125_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191912366","article-title":"Price and prejudice? The value of chimeric antigen receptor (CAR) T-cell therapy","volume":"19","author":"Choi","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101125_bib0025","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0026","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/2326-6066.CIR-20-0253","article-title":"CD28 costimulatory domain-targeted mutations enhance chimeric antigen receptor T-cell function","volume":"9","author":"Boucher","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"44","key":"10.1016\/j.ctarc.2026.101125_bib0027","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2405085121","article-title":"Dual ON\/OFF-switch chimeric antigen receptor controlled by two clinically approved drugs","volume":"121","author":"Giordano Attianese","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ctarc.2026.101125_bib0028","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0029","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/cells11010021","article-title":"Natural receptor- and ligand-based chimeric antigen receptors: strategies using natural ligands and receptors for targeted cell killing","volume":"11","author":"Branella","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-024-06770-w","article-title":"CD28 hinge used in chimeric antigen receptor (CAR) T-cells exhibits local structure and conformational exchange amidst global disorder","volume":"7","author":"Folimonova","year":"2024","journal-title":"Commun. Biol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101125_bib0031","article-title":"Non-signaling but all important: how the linker, hinge, and transmembrane domains in the CAR hold it all together","volume":"16","author":"Bernard","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101125_bib0032","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/bjh.19631","article-title":"Development of novel humanized CD19\/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms","volume":"205","author":"Wu","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101125_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009486","article-title":"EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses","volume":"12","author":"Lertsumitkul","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ctarc.2026.101125_bib0034","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/cancers14030497","article-title":"Challenges and advances in chimeric antigen receptor therapy for acute myeloid leukemia","volume":"14","author":"Marvin-Peek","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0035","doi-asserted-by":"crossref","DOI":"10.1007\/s12026-025-09687-6","article-title":"Engineering CAR-T cells for solid tumors: bispecific antigen targeting, tumor microenvironment modulation, and toxicity control","volume":"73","author":"Premchandani","year":"2025","journal-title":"Immunol. Res."},{"key":"10.1016\/j.ctarc.2026.101125_bib0036","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101125_bib0037","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ctarc.2026.101125_bib0038","doi-asserted-by":"crossref","unstructured":"Mishra, H.J., Mahoney, L., Smith, D.R., Kalcheim, L., Kansal, K., Murren, N., Chang, M., Richards, R.M., & Brockman, J.M. (2025). Chimeric antigen receptors transmit co-stimulatory domain dependent piconewton forces to their target. bioRxiv. https:\/\/doi.org\/10.1101\/2025.10.22.683904.","DOI":"10.1101\/2025.10.22.683904"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0039","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34141-8","article-title":"speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing","volume":"13","author":"Castellanos-Rueda","year":"2022","journal-title":"Nat. Commun."},{"issue":"670","key":"10.1016\/j.ctarc.2026.101125_bib0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm1463","article-title":"Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies","volume":"14","author":"Goodman","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0041","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/antib14010016","article-title":"Immune cell engagers: advancing precision immunotherapy for cancer treatment","volume":"14","author":"In","year":"2025","journal-title":"Antibodies"},{"key":"10.1016\/j.ctarc.2026.101125_bib0042","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0043","doi-asserted-by":"crossref","DOI":"10.1155\/jimr\/5845167","article-title":"Advancements and future directions of dual-target chimeric antigen receptor T-cell therapy in preclinical and clinical studies","volume":"2025","author":"Zhang","year":"2025","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.ctarc.2026.101125_bib0044","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024025440","article-title":"A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy in B cell acute lymphoblastic leukemia. [Manuscript sub mitted for publication]","author":"Falg\u00e0s","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54794-x","article-title":"Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK\/STAT signaling pathway","volume":"15","author":"Adachi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2026.101125_bib0046","doi-asserted-by":"crossref","unstructured":"Seif, F., Khoshmirsafa, M., Aazami, H., Mohsenzadegan, M., Sedighi, G., & Bahar, M. (2017). The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun. Signal.: CCS, 15(1). https:\/\/doi.org\/10.1186\/s12964-017-0177-y.","DOI":"10.1186\/s12964-017-0177-y"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0047","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0048","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ctarc.2026.101125_bib0049","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2026.101125_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1615212","article-title":"Tracing the development of CAR-T cell design: from concept to next-generation platforms","volume":"16","author":"Alsaieedi","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2026.101125_bib0051","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101125_bib0052","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101125_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.841425","article-title":"Update for advance CAR-T therapy in solid tumors, clinical application in peritoneal carcinomatosis from colorectal cancer and future prospects","volume":"13","author":"Qian","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101125_bib0054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0327322","article-title":"Precision-cut tumor tissue slices, a novel tool to study the tumor microenvironment interactions with chimeric antigen receptor (CAR) T cells","volume":"20","author":"Durante","year":"2025","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101125_bib0055","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3390\/ijms23031833","article-title":"Granzymes: the molecular executors of immune-mediated cytotoxicity","volume":"23","author":"Hay","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101125_bib0056","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41563-024-01825-z","article-title":"Lyophilized lymph nodes for improved delivery of chimeric antigen receptor T cells","volume":"23","author":"Shi","year":"2024","journal-title":"Nat. Mater."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101125_bib0057","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/s43018-025-01009-x","article-title":"CAR-engineered lymphocyte persistence is governed by a FAS ligand\u2013FAS autoregulatory circuit","volume":"6","author":"Yi","year":"2025","journal-title":"Nat. Cancer"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101125_bib0058","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.3390\/cells10123390","article-title":"NK cells armed with chimeric antigen receptors (CAR): roadblocks to successful development","volume":"10","author":"Bashiri Dezfouli","year":"2021","journal-title":"Cells"},{"issue":"19","key":"10.1016\/j.ctarc.2026.101125_bib0059","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.3390\/jcm12196124","article-title":"Exploring CAR-T cell therapy side effects: mechanisms and management strategies","volume":"12","author":"Zhang","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ctarc.2026.101125_bib0060","article-title":"Advances in CAR-NK cell therapy for hematological malignancies","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0061","doi-asserted-by":"crossref","DOI":"10.1080\/20565623.2024.2422786","article-title":"Cytokine release syndrome caused by immune checkpoint inhibitors: a case report and literature review","volume":"10","author":"Zhang","year":"2024","journal-title":"Future Sci. OA"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101125_bib0062","article-title":"Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment","volume":"14","author":"Gu","year":"2022","journal-title":"WIREs Mech. Dis."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101125_bib0063","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1007\/s11030-023-10805-5","article-title":"Taming the cytokine storm: small molecule inhibitors targeting IL-6\/IL-6\u03b1 receptor","volume":"28","author":"Zia","year":"2024","journal-title":"Mol. Divers"},{"key":"10.1016\/j.ctarc.2026.101125_bib0064","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1325860","article-title":"Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case report","volume":"15","author":"Zhong","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01048-0","article-title":"Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"14","author":"Costa","year":"2024","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0066","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0067","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40164-021-00209-2","article-title":"Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"issue":"37","key":"10.1016\/j.ctarc.2026.101125_bib0068","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1039\/D2TB00592A","article-title":"Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy","volume":"10","author":"Balagopal","year":"2022","journal-title":"J. Mater. Chem. B"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101125_bib0069","first-page":"221","article-title":"Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy","author":"Lin","year":"2024","journal-title":"J. Exp. Med."},{"issue":"18","key":"10.1016\/j.ctarc.2026.101125_bib0070","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.12998\/wjcc.v12.i18.3555","article-title":"Cytokine release syndrome triggered by programmed death 1 blockade (sintilimab) therapy in a psoriasis patient: a case report","volume":"12","author":"Zhou","year":"2024","journal-title":"World J. Clin. Cases"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101125_bib0071","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/biom13020382","article-title":"Early use of corticosteroids following CAR T-cell therapy correlates with reduced risk of high-grade CRS without negative impact on neurotoxicity or treatment outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101125_bib0072","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjh.18335","article-title":"Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: a systematic review and meta-analysis","volume":"198","author":"Shargian","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101125_bib0073","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/cimb47020090","article-title":"Chimeric antigen receptor cell therapy: empowering treatment strategies for solid tumors","volume":"47","author":"Jaing","year":"2025","journal-title":"Curr. Issues. Mol. Biol."},{"key":"10.1016\/j.ctarc.2026.101125_bib0074","article-title":"Recent progress and future perspectives of immunotherapy in advanced gastric cancer","volume":"13","author":"Jin","year":"2022","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101125_bib0075","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41434-021-00237-x","article-title":"Retroviral gene therapy in Germany with a view on previous experience and future perspectives","volume":"28","author":"Morgan","year":"2021","journal-title":"Gene Ther."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101125_bib0076","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41375-024-02351-2","article-title":"Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia","volume":"38","author":"Atar","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2026.101125_bib0077","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0078","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1038\/s41467-023-38723-y","article-title":"Neutralizing IFN\u03b3 improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies","volume":"14","author":"Manni","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2026.101125_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107385","article-title":"The shifting therapeutic paradigm for relapsed\/refractory mantle cell lymphoma","volume":"134","author":"Arun Kumar","year":"2023","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ctarc.2026.101125_bib0080","unstructured":"Visit: www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/UCM376521.pdf."},{"key":"10.1016\/j.ctarc.2026.101125_bib0081","unstructured":"Visit: www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/."},{"key":"10.1016\/j.ctarc.2026.101125_bib0082","unstructured":"Visit: www.fda.gov\/\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/UCM585417.pdf."},{"key":"10.1016\/j.ctarc.2026.101125_bib0083","unstructured":"Visit: www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/UCM585403.pdf."},{"key":"10.1016\/j.ctarc.2026.101125_bib0084","unstructured":"Visit: www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/UCM585414.pdf."},{"key":"10.1016\/j.ctarc.2026.101125_bib0085","unstructured":"Visit: www.ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol10\/atmp_guidelines_en.pdf."},{"key":"10.1016\/j.ctarc.2026.101125_bib0086","unstructured":"Visit: www.ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol10\/atmp_guidelines_en.pdf."},{"issue":"8\u20139","key":"10.1016\/j.ctarc.2026.101125_bib0087","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41417-021-00418-1","article-title":"Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study","volume":"29","author":"Sheykhhasan","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101125_bib0088","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/XCS.0000000000000964","article-title":"Using oncolytic virus to retask CD19-chimeric antigen receptor T cells for treatment of pancreatic cancer: toward a universal chimeric antigen receptor T-cell strategy for solid tumor","volume":"238","author":"Chen","year":"2024","journal-title":"J. Am. Coll. Surg."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101125_bib0089","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231235","article-title":"Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy","volume":"220","author":"Marone","year":"2023","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ctarc.2026.101125_bib0090","article-title":"Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.ctarc.2026.101125_bib0091","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145459","article-title":"BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia","volume":"131","author":"Kong","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0092","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20488-3","article-title":"CXCR5 CAR-T cells simultaneously target B cell non-hodgkin\\u2019s lymphoma and tumor-supportive follicular T helper cells","volume":"12","author":"Bunse","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0093","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-024-13400-5","article-title":"Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed\/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis","volume":"25","author":"Meng","year":"2025","journal-title":"BMC Cancer"},{"issue":"Suppl 15","key":"10.1016\/j.ctarc.2026.101125_bib0094","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies","volume":"12","author":"Sanchez","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.ctarc.2026.101125_bib0095","series-title":"American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting","article-title":"Emerging novel functional imaging and immunotherapy in renal cell carcinoma and current treatment sequencing strategies after immunotherapy","volume":"44","author":"Ali","year":"2024"},{"key":"10.1016\/j.ctarc.2026.101125_bib0096","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2021.11.018","article-title":"Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma","volume":"24","author":"Zhang","year":"2021","journal-title":"Mol. Therapy - Oncolytics"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101125_bib0097","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3390\/diagnostics14080819","article-title":"CAR-T cell therapy in ovarian cancer: where are we now?","volume":"14","author":"Cutri-French","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.ctarc.2026.101125_bib0098","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/07357907.2022.2069254","article-title":"Three third-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: similarities and differences","author":"Chen","year":"2022","journal-title":"Cancer Invest."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101125_bib0099","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.7150\/ijbs.70120","article-title":"CAR-T cell therapy for breast cancer: from basic research to clinical application","volume":"18","author":"Yang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101125_bib0100","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009960","article-title":"Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells","volume":"12","author":"Qi","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"26","key":"10.1016\/j.ctarc.2026.101125_bib0101","first-page":"1","article-title":"Genetically modified T-cell-based adoptive immunotherapy in hematological malignancies","volume":"2017","author":"Ye","year":"2017","journal-title":"J. Immunol. Res."},{"issue":"13","key":"10.1016\/j.ctarc.2026.101125_bib0102","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/cells13131075","article-title":"Evaluation of the immunomodulatory effects of radiation for chimeric antigen receptor T cell therapy in glioblastoma multiforme","volume":"13","author":"Akhavan","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0103","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1973783","article-title":"Innate-like NKp30 + CD8 + T cells armed with TCR\/CAR target tumor heterogeneity","volume":"10","author":"Correia","year":"2021","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101125_bib0104","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101125_bib0105","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1007\/s00262-023-03573-6","article-title":"Spatial immune composition of tumor microenvironment in patients with pancreatic cancer","volume":"72","author":"Zwart","year":"2023","journal-title":"Cancer Immunol. Immunther."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0106","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1038\/s41467-024-49171-7","article-title":"Dissecting tumor microenvironment from spatially resolved transcriptomics data by heterogeneous graph learning","volume":"15","author":"Zuo","year":"2024","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101125_bib0107","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.3390\/cancers15102824","article-title":"T-cell engagers in solid cancers\u2014current landscape and future directions","volume":"15","author":"Shanshal","year":"2023","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101125_bib0108","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-025-02923-x","article-title":"CAR T-cell therapy in hematologic and solid malignancies: mechanisms, clinical applications, and future directions","volume":"42","author":"Kuttiappan","year":"2025","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0109","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-022-03285-y","article-title":"B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages","volume":"20","author":"Nobari","year":"2022","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101125_bib0110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008566","article-title":"Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity","volume":"12","author":"Shabaneh","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"81","key":"10.1016\/j.ctarc.2026.101125_bib0111","doi-asserted-by":"crossref","first-page":"eadf1426","DOI":"10.1126\/sciimmunol.adf1426","article-title":"CD19 CAR antigen engagement mechanisms and affinity tuning","volume":"8","author":"He","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ctarc.2026.101125_bib0112","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101125_bib0113","doi-asserted-by":"crossref","first-page":"12569","DOI":"10.1002\/cam4.5907","article-title":"Therapeutic effects of anti-GM2 CAR-T cells expressing IL-7 and CCL19 for GM2-positive solid cancer in xenograft model","volume":"12","author":"Sasaki","year":"2023","journal-title":"Cancer Med."},{"issue":"21","key":"10.1016\/j.ctarc.2026.101125_bib0114","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1097\/CM9.0000000000002944","article-title":"Development of a novel HER2-CAR monocyte cell therapy with controllable proliferation and enhanced anti-tumor efficacy","volume":"137","author":"Yang","year":"2024","journal-title":"Chin. Med. J."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jcyt.2022.10.007","article-title":"Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells","volume":"25","author":"Halliwell","year":"2023","journal-title":"Cytotherapy"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101125_bib0116","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1021\/acsnano.4c01597","article-title":"Engineering a programmed death-ligand 1-targeting monobody via directed evolution for Syn notch-gated cell therapy","volume":"18","author":"Zhu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.ctarc.2026.101125_bib0117","doi-asserted-by":"crossref","unstructured":"Yang Z., Liu Y., Zaho H. CAR T treatment beyond cancer: hope for immunomodulatory therapy of non-cancerous diseases. 2024; 344:122556. https:\/\/doi.org\/10.1016\/j.lfs.2024.122556.","DOI":"10.1016\/j.lfs.2024.122556"},{"key":"10.1016\/j.ctarc.2026.101125_bib0118","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1396395","article-title":"Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma","volume":"14","author":"Pang","year":"2024","journal-title":"Front. Oncol."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101125_bib0119","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/CM9.0000000000002549","article-title":"Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies","volume":"136","author":"Yang","year":"2023","journal-title":"Chin. Med. J."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101125_bib0120","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat. Cancer"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101125_bib0121","doi-asserted-by":"crossref","DOI":"10.31083\/j.fbl2809206","article-title":"Present status and advances in chimeric antigen receptor T cell therapy for glioblastoma","volume":"28","author":"Zhou","year":"2023","journal-title":"Front. Biosci. - Landmark"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101125_bib0122","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/1744666X.2021.1880895","article-title":"Chimeric antigen receptor T cell therapy for melanoma","volume":"17","author":"Razavi","year":"2021","journal-title":"Expert. Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0123","article-title":"Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101125_bib0124","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/BOR.0000000000000994","article-title":"Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0","volume":"36","author":"Appalaneni","year":"2024","journal-title":"Curr. Opin. Rheumatol."},{"issue":"November","key":"10.1016\/j.ctarc.2026.101125_bib0125","first-page":"1","article-title":"Chimeric antigen receptor T-cell therapy in lung cancer: potential and challenges","volume":"12","author":"Xiao","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101125_bib0126","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2026.101125_bib0127","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1396490","article-title":"Mechanisms and management of CAR T toxicity","volume":"14","author":"Ferreri","year":"2024","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101125_bib0128","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5603\/AHP.a2022.0020","article-title":"Outpatient CAR-T therapy","volume":"53","author":"Dytfeld","year":"2022","journal-title":"Acta Haematol. Pol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101125_bib0129","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052631","article-title":"Chimeric antigen receptor T cell therapy for hepatocellular carcinoma: where do we stand?","volume":"25","author":"Aggeletopoulou","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101125_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5812\/tms.114656","article-title":"Chimeric antigen receptor T-cell therapy: an overview of the changing face of cancer immunotherapy","volume":"2","author":"Safarzadeh Kozani","year":"2021","journal-title":"Trends Med. Sci."},{"issue":"26","key":"10.1016\/j.ctarc.2026.101125_bib0131","article-title":"Recent advances in universal chimeric antigen receptor T cell therapy","volume":"18","author":"Jiang","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101125_bib0132","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3390\/cancers12040842","article-title":"Chimeric antigen receptor cell therapy: overcoming obstacles to battle cancer","volume":"12","author":"Petty","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2026.101125_bib0133","doi-asserted-by":"crossref","unstructured":"S. Liu, Y. Zhang, and Y. Zhang Biotherapy Center, \u201cChallenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors,\u201d vol. 03545815, no. 5, pp. 239\u2013244, 2023, doi: 10.21147\/j.issn.1000-9604.2023.03.03.","DOI":"10.21147\/j.issn.1000-9604.2023.03.03"},{"key":"10.1016\/j.ctarc.2026.101125_bib0134","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12943-025-02334-6","article-title":"Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy","volume":"24","author":"Lu","year":"2025","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101125_bib0135","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1631\/jzus.B2200256","article-title":"Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches","volume":"23","author":"Gu","year":"2022","journal-title":"J. Zhejiang. Univ. Sci. B"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101125_bib0136","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/2643-3230.BCD-20-0122","article-title":"Dual targeting with CAR T cells to limit antigen escape in multiple myeloma","volume":"1","author":"Simon","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.ctarc.2026.101125_bib0137","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114358","article-title":"Advances in modular control of CAR-T therapy with adapter-mediated CARs","volume":"187","author":"McCue","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ctarc.2026.101125_bib0138","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1613222","article-title":"Dual targeting of BCMA and SLAMF7 with the CARtein system: chimeric antigen receptors with intein-mediated splicing elicit specific T cell activation against multiple myeloma","volume":"16","author":"Moares","year":"2025","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101125_bib0139","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101125_bib0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.997482","article-title":"Treatment of aggressive T-cell lymphoma\/leukemia with anti-CD4 CAR T cells","volume":"13","author":"Feng","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2026.101125_bib0141","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.915342","article-title":"CAR T-cell therapies in Italy: patient access barriers and recommendations for health system solutions","volume":"13","author":"Jommi","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101125_bib0142","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1462697","article-title":"Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR\/Cas9","volume":"15","author":"Amiri","year":"2024","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101125_bib0143","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1111\/cas.14993","article-title":"CAR-NK cell in cancer immunotherapy; a promising frontier","volume":"112","author":"Marofi","year":"2021","journal-title":"Cancer Sci."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:53:13Z","timestamp":1780919593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226000365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":143,"alternative-id":["S2468294226000365"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101125","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T- cell therapy: A promising novel approach for treatment of cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101125"}}